The Footnote

Pharmacists on the Front Line: WA’s Bold Trial to Expand Healthcare Access

Author attribution not recorded

A conceptual layout showing two diverging paths marked by medical symbols, meeting at a point of uncertain integration.

By The Footnote News Desk

Western Australia is set to become the latest battleground in the push to redefine primary healthcare roles, as the Enhanced Access Community Pharmacy Pilot (EACPP) moves from planning to rollout. The program will allow accredited pharmacists to diagnose, treat, and prescribe for a set list of common conditions — a move heralded by some as overdue innovation and condemned by others as risky fragmentation of care.

From UTIs to Asthma — A Scope Expansion

Since 2023, WA pharmacists have been able to treat uncomplicated urinary tract infections in women aged 18–65, dispensing first-line antibiotics under strict protocols.

From 2025, that scope will grow. Pharmacists who complete a Graduate Certificate in Prescribing — accredited by the Australian Pharmacy Council — will be able to treat:

  • Acute ear infections

  • Mild-to-moderate acne

  • Asthma management and medication supply

  • Resupply of the oral contraceptive pill

UTI treatment will continue, but now as part of a broader, more structured prescribing role. The first cohort of pharmacists will begin training in September 2025, with full service rollout anticipated between 2027–2028.

Policy Meets Politics

The WA Government says the trial addresses two critical pressures: GP shortages and hospital bottlenecks. It is backed by a $1.26 million investment in rural and remote pharmacy subsidies, aiming to bring timely care to regions where seeing a GP can mean weeks of waiting.

Health Minister Amber-Jade Sanderson insists safety will be ensured through rigorous training, My Health Record integration, and clear referral pathways to GPs when cases fall outside pharmacist scope.

The Pushback

Medical groups have been quick to warn of the risks. The Royal Australian College of General Practitioners (WA) and Australian Medical Association (WA) argue that community pharmacy clinics could increase misdiagnosis rates, overprescribing, and antimicrobial resistance.

AMA (WA) president Dr Michael Page told the ABC the model “shifts care away from continuity” and risks “treating symptoms, not causes.” Both organisations have called for stronger evaluation metrics and mandatory data reporting.

National Context

WA’s trial mirrors moves in other states. Queensland has already made pharmacist prescribing permanent for several conditions, while Victoria and New South Wales are running similar pilots. Internationally, UK and New Zealand pharmacists already operate under expanded prescribing rights.

The WA trial, however, will be one of the most structured in Australia — requiring postgraduate qualifications and incorporating specialist training modules rather than short courses.

What’s Next?

As applications open, the profession remains divided. For some, this is the future of integrated care — utilising the untapped skills of pharmacists to plug primary care gaps. For others, it’s a risky experiment that could further fracture an already strained health system.

Evaluation data will be critical. The government says outcomes, safety incidents, and patient satisfaction will be monitored throughout, informing whether the model becomes permanent policy.

The question now is not whether pharmacists can step into these roles — but whether the system can balance access, safety, and collaboration without igniting a turf war that patients ultimately pay for.

Simplified complete reading view